WO2003008412A3 - Hetero-bicyclic crf antagonists - Google Patents

Hetero-bicyclic crf antagonists Download PDF

Info

Publication number
WO2003008412A3
WO2003008412A3 PCT/EP2002/007865 EP0207865W WO03008412A3 WO 2003008412 A3 WO2003008412 A3 WO 2003008412A3 EP 0207865 W EP0207865 W EP 0207865W WO 03008412 A3 WO03008412 A3 WO 03008412A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
halo
alkoxy
nr6r7
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/007865
Other languages
French (fr)
Other versions
WO2003008412A2 (en
Inventor
Fabio Romano Di
Fabrizio Micheli
Yves St-Denis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0400465A priority Critical patent/HUP0400465A2/en
Priority to NZ530043A priority patent/NZ530043A/en
Priority to CA002451530A priority patent/CA2451530A1/en
Priority to MXPA04000494A priority patent/MXPA04000494A/en
Priority to JP2003513971A priority patent/JP4459616B2/en
Priority to EP02764696A priority patent/EP1425280B1/en
Priority to KR1020047000696A priority patent/KR100961287B1/en
Priority to IL15925402A priority patent/IL159254A0/en
Priority to PL02368053A priority patent/PL368053A1/en
Priority to DE60214401T priority patent/DE60214401T2/en
Priority to US10/483,792 priority patent/US7253284B2/en
Priority to KR1020097020632A priority patent/KR20090110386A/en
Priority to HK04109443.0A priority patent/HK1066535B/en
Priority to SI200230419T priority patent/SI1425280T1/en
Priority to AU2002328899A priority patent/AU2002328899B2/en
Priority to BR0211171-3A priority patent/BR0211171A/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of WO2003008412A2 publication Critical patent/WO2003008412A2/en
Publication of WO2003008412A3 publication Critical patent/WO2003008412A3/en
Priority to NO20040206A priority patent/NO20040206L/en
Anticipated expiration legal-status Critical
Priority to CY20061101650T priority patent/CY1105780T1/en
Priority to US11/749,433 priority patent/US20070219232A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof, wherein R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups selected from: halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, -C(O)R5, nitro, -NR6R7, cyano, and a group R8; R1 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR6R7 or cyano; R2 is hydrogen, C3-C7 cycloalkyl, or a group R9; R3 is C3-C7 cycloalkyl, or a group R9; or R2 and R3 together with N form a 5-14 membered heterocycle, which may be substituted 1 to 3 R10 groups; R4 is hydrogen, C1-C6 alkyl, halogen or halo C1-C6 alkyl; R5 is a C1-C4 alkyl, -OR6 or NR6R7; R6 is hydrogen or C1-C6 alkyl; R7 is hydrogen or C1-C6 alkyl; R8 is a 5-6 membered heterocycle, which may be saturated or may contain one to three double bonds, and which may be substituted by 1 or more R11 groups; R9 is a C1-C6 alkyl that may be substituted by one or more groups selected from: C3-C7 cycloalkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, hydroxy, halo C1-C6 alkyl; R10 is a group R8, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, hydroxy, halogen, nitro, cyano, C(O)NR6R7, phenyl which may be substituted by 1 to 4 R11 groups; R11 is C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, hydroxy, halogen, nitro, cyano, or C(O)NR6R7; X is carbon or nitrogen; n is 1 or 2; to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).
PCT/EP2002/007865 2001-07-17 2002-07-15 Hetero-bicyclic crf antagonists Ceased WO2003008412A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
US10/483,792 US7253284B2 (en) 2001-07-17 2002-07-15 Chemical compounds
CA002451530A CA2451530A1 (en) 2001-07-17 2002-07-15 Chemical compounds
MXPA04000494A MXPA04000494A (en) 2001-07-17 2002-07-15 Chemical compounds.
JP2003513971A JP4459616B2 (en) 2001-07-17 2002-07-15 Heterobicyclic CRF antagonist
EP02764696A EP1425280B1 (en) 2001-07-17 2002-07-15 Hetero-bicyclic crf antagonists
NZ530043A NZ530043A (en) 2001-07-17 2002-07-15 Hetero-bicyclic CRF antagonists
IL15925402A IL159254A0 (en) 2001-07-17 2002-07-15 Hetero-bicyclic crf antagonists
PL02368053A PL368053A1 (en) 2001-07-17 2002-07-15 Chemical compounds
DE60214401T DE60214401T2 (en) 2001-07-17 2002-07-15 HETERO BICYCLIC CRF ANTAGONISTS
KR1020097020632A KR20090110386A (en) 2001-07-17 2002-07-15 Hetero-bicyclic CrF antagonist
KR1020047000696A KR100961287B1 (en) 2001-07-17 2002-07-15 Hetero-bicyclic CrF antagonist
HU0400465A HUP0400465A2 (en) 2001-07-17 2002-07-15 Corticotropin-releasing factor (crf) receptor antagonists bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
SI200230419T SI1425280T1 (en) 2001-07-17 2002-07-15 HETERO-BICYCLIC ANTAGONISTS CRF
AU2002328899A AU2002328899B2 (en) 2001-07-17 2002-07-15 Hetero-bicyclic CRF antagonists
BR0211171-3A BR0211171A (en) 2001-07-17 2002-07-15 Chemical compounds
HK04109443.0A HK1066535B (en) 2001-07-17 2002-07-15 Hetero-bicyclic crf antagonists
NO20040206A NO20040206L (en) 2001-07-17 2004-01-16 Chemical connections
CY20061101650T CY1105780T1 (en) 2001-07-17 2006-11-14 ETO-BICYCLIC CRF COMPETITORS
US11/749,433 US20070219232A1 (en) 2001-07-17 2007-05-16 Chemical Compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0117396.2A GB0117396D0 (en) 2001-07-17 2001-07-17 Chemical compounds
GB0117396.2 2001-07-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/749,433 Continuation US20070219232A1 (en) 2001-07-17 2007-05-16 Chemical Compounds

Publications (2)

Publication Number Publication Date
WO2003008412A2 WO2003008412A2 (en) 2003-01-30
WO2003008412A3 true WO2003008412A3 (en) 2003-05-01

Family

ID=9918655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007865 Ceased WO2003008412A2 (en) 2001-07-17 2002-07-15 Hetero-bicyclic crf antagonists

Country Status (26)

Country Link
US (2) US7253284B2 (en)
EP (2) EP1695974B1 (en)
JP (1) JP4459616B2 (en)
KR (2) KR20090110386A (en)
CN (1) CN100447141C (en)
AT (2) ATE338042T1 (en)
AU (1) AU2002328899B2 (en)
BR (1) BR0211171A (en)
CA (1) CA2451530A1 (en)
CO (1) CO5550437A2 (en)
CY (1) CY1105780T1 (en)
DE (2) DE60235729D1 (en)
DK (1) DK1425280T3 (en)
ES (2) ES2271327T3 (en)
GB (2) GB0117396D0 (en)
HU (1) HUP0400465A2 (en)
IL (1) IL159254A0 (en)
MX (1) MXPA04000494A (en)
NO (1) NO20040206L (en)
NZ (1) NZ530043A (en)
PL (1) PL368053A1 (en)
PT (1) PT1425280E (en)
RU (1) RU2310655C2 (en)
SI (1) SI1425280T1 (en)
WO (1) WO2003008412A2 (en)
ZA (1) ZA200309708B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462622B2 (en) * 2001-06-12 2008-12-09 Glaxo Group Limited Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists
DE602004005960T2 (en) * 2003-01-16 2008-01-17 Sb Pharmco Puerto Rico Inc. HETEROARYL-SUBSTITUTED PYRROLÄ2, 3-BÜPYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
CA2550948A1 (en) 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc. Crf receptor antagonists and methods relating thereto
DE602005014375D1 (en) * 2004-10-19 2009-06-18 Neurocrine Biosciences Inc CRF receptor antagonists and associated methods
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
US8513420B2 (en) 2007-03-19 2013-08-20 Monika Mazik Amino-naphthyridine derivatives
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009008552A1 (en) * 2007-07-11 2009-01-15 Taisho Pharmaceutical Co., Ltd. 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2896187A1 (en) 2013-01-18 2014-07-24 F. Hoffmann-La Roche Ag 3-substituted pyrazoles and use as dlk inhibitors
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033750A1 (en) * 1994-06-08 1995-12-14 Pfizer Inc. Corticotropin releasing factor antagonists
WO1998008846A1 (en) * 1996-08-27 1998-03-05 Pfizer Inc. Substituted 6,6-hetero-bicyclic derivatives

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO152788C (en) * 1978-08-31 1985-11-20 Otsuka Pharma Co Ltd ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PIPERAZINYLBENZOHETEROCYCLIC COMPOUNDS.
US5169857A (en) 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
NO177005C (en) 1988-01-20 1995-07-05 Bayer Ag Analogous process for the preparation of substituted pyridines, as well as intermediates for use in the preparation
GB2248618B (en) 1988-06-17 1993-01-06 Wyeth John & Brother Ltd Process for preparing pyridine derivatives
CA2022408A1 (en) 1989-08-31 1991-03-01 Michael P. Bodman Process for preparing pyridine carboxylic acid derivatives
JP2541702B2 (en) 1989-10-11 1996-10-09 帝人株式会社 Bicyclic pyrimidine derivative, method for producing the same, and pharmaceutical preparation containing the same as an active ingredient
DE4022414A1 (en) 1990-07-13 1992-01-16 Bayer Ag SUBSTITUTED PYRROLO-PYRIDINE
WO1992012718A1 (en) 1991-01-23 1992-08-06 Gensia, Inc. Adenosine kinase inhibitors
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
GB9125842D0 (en) 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
FI944602A0 (en) 1992-04-03 1994-10-03 Upjohn Co Pharmaceutically active bicyclic-heterocyclic amines
JPH0710876A (en) 1993-06-24 1995-01-13 Teijin Ltd Pyrrolo [2,3-d] pyrimidine having a cyclic amino group at the 4-position
RU2153494C2 (en) 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-alkyl-n-arylpyrimodineamines, method of patient treatment, pharmaceutical composition
PL313973A1 (en) 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
WO1995034563A1 (en) 1994-06-16 1995-12-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
AU738304B2 (en) 1995-10-13 2001-09-13 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands
US5955613A (en) 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
US6492520B1 (en) 1996-08-06 2002-12-10 Pfizer Inc Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
IL127566A0 (en) * 1996-08-28 1999-10-28 Pfizer Substituted 6,5-hetero- bicyclic derivatives
JP2001511813A (en) 1997-02-18 2001-08-14 ニューロクライン バイオサイエンシーズ,インコーポレイテッド CRF receptor antagonists and related methods
ID24300A (en) 1997-08-05 2000-07-13 Pfizer Prod Inc 4-AMINOPIROL (3,2-d) PYRIMIDINE AS AN NEUROPEPTIDE RECEPTOR ANTAGONISTS
JP2002510687A (en) 1998-04-02 2002-04-09 ニューロゲン コーポレイション Aminoalkyl-substituted pyrrolo [2,3-B] pyridine and pyrrolo [2,3-D] pyrimidine derivatives: modulators of the CRF1 receptor
JPH11335376A (en) 1998-05-25 1999-12-07 Taisho Pharmaceut Co Ltd Aryltetrahydropyridine derivative
JP2000086663A (en) 1998-09-09 2000-03-28 Taisho Pharmaceut Co Ltd Aryltetrahydropyridine derivative
JP2002540206A (en) 1999-03-11 2002-11-26 ニューロゲン コーポレイション Aryl-fused 2,4-disubstituted pyridines: NK3 receptor ligands
JP2002540203A (en) 1999-03-29 2002-11-26 ニューロゲン コーポレイション 4-Substituted quinoline derivatives as NK-3 and / or GABA (A) receptor ligands
FR2791675B1 (en) 1999-03-30 2001-05-04 Synthelabo DERIVATIVES OF N- [2- (4-AMINOPHENYL) ETHYL] -2,3-DIHYDRO-1,4- BENZODIOXINNE-2-METHANAMINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
IL148903A0 (en) 1999-09-30 2002-09-12 Neurogen Corp Certain alkylene diamine-substituted heterocycles
US6525067B1 (en) 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
HRP20020599A2 (en) 2000-01-18 2004-08-31 Pfizer Prod Inc Corticotropin releasing factor antagonists
AR028782A1 (en) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd TETRAHYDROPIRIDINE OR PIPERIDINE HETEROCICLIC DERIVATIVES
WO2002019975A1 (en) 2000-09-05 2002-03-14 Taisho Pharmaceutical Co., Ltd. Hair growth stimulants
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
IL158062A0 (en) 2001-04-30 2004-03-28 Glaxo Group Ltd Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
US7462622B2 (en) 2001-06-12 2008-12-09 Glaxo Group Limited Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists
AU2002336462A1 (en) 2001-09-06 2003-03-24 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
SE0201980D0 (en) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
DE602004005960T2 (en) 2003-01-16 2008-01-17 Sb Pharmco Puerto Rico Inc. HETEROARYL-SUBSTITUTED PYRROLÄ2, 3-BÜPYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS
EP1592690A1 (en) 2003-02-14 2005-11-09 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033750A1 (en) * 1994-06-08 1995-12-14 Pfizer Inc. Corticotropin releasing factor antagonists
WO1998008846A1 (en) * 1996-08-27 1998-03-05 Pfizer Inc. Substituted 6,6-hetero-bicyclic derivatives

Also Published As

Publication number Publication date
NZ530043A (en) 2006-03-31
GB0117396D0 (en) 2001-09-05
ES2271327T3 (en) 2007-04-16
CN100447141C (en) 2008-12-31
PL368053A1 (en) 2005-03-21
RU2004104349A (en) 2005-03-27
CA2451530A1 (en) 2003-01-30
RU2310655C2 (en) 2007-11-20
US20070219232A1 (en) 2007-09-20
EP1425280A2 (en) 2004-06-09
GB2378702A (en) 2003-02-19
KR20090110386A (en) 2009-10-21
DE60214401T2 (en) 2007-02-22
IL159254A0 (en) 2004-06-01
WO2003008412A2 (en) 2003-01-30
GB0216041D0 (en) 2002-08-21
CO5550437A2 (en) 2005-08-31
EP1695974A1 (en) 2006-08-30
EP1425280B1 (en) 2006-08-30
ATE461197T1 (en) 2010-04-15
ZA200309708B (en) 2005-01-21
CY1105780T1 (en) 2011-02-02
SI1425280T1 (en) 2006-12-31
BR0211171A (en) 2004-08-10
CN1525972A (en) 2004-09-01
US7253284B2 (en) 2007-08-07
KR20040023651A (en) 2004-03-18
MXPA04000494A (en) 2004-05-04
EP1695974B1 (en) 2010-03-17
DE60214401D1 (en) 2006-10-12
HUP0400465A2 (en) 2005-01-28
ATE338042T1 (en) 2006-09-15
NO20040206L (en) 2004-03-16
US20040171607A1 (en) 2004-09-02
HK1066535A1 (en) 2005-03-24
DK1425280T3 (en) 2007-01-02
DE60235729D1 (en) 2010-04-29
KR100961287B1 (en) 2010-06-04
PT1425280E (en) 2006-12-29
AU2002328899B2 (en) 2006-12-21
JP2005514328A (en) 2005-05-19
JP4459616B2 (en) 2010-04-28
ES2342417T3 (en) 2010-07-06

Similar Documents

Publication Publication Date Title
WO2003008412A3 (en) Hetero-bicyclic crf antagonists
TW200508232A (en) Bicyclic derivatives, their preparation, pharmaceutical compositions containing them and their use in therapy
GB0226724D0 (en) Therapeutic agents
MXPA02012033A (en) 2-aminocarbonyl-9h-purine derivatives.
MY131019A (en) Tropane derivatives useful in therapy
YU95102A (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
MXPA03005464A (en) Antiviral agents.
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
MXPA05012247A (en) New benzimidazole derivatives.
TW200512201A (en) New heterocyclic amides
TWI264437B (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
UA85502C2 (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
ATE397609T1 (en) CORTICOTROPINE RELEASE FACTOR ANTAGONISTS
TNSN02096A1 (en) Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
MXPA02012426A (en) Novel compounds.
IL159521A0 (en) Tricyclic pyridines for use in treatment of conditions mediated by crf
EA200200379A3 (en) Pyrimidin-4-one compounds, process for their preparation and pharmaceutical compositions containing them
AP2001002179A0 (en) 2-Aminocarbonyl-9h-purine derivatives.
SE0100344D0 (en) New Use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 159254

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002764696

Country of ref document: EP

Ref document number: 530043

Country of ref document: NZ

Ref document number: 02137/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003/09708

Country of ref document: ZA

Ref document number: 200309708

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2451530

Country of ref document: CA

Ref document number: 2002328899

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002813866X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10483792

Country of ref document: US

Ref document number: 1-2004-500068

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003513971

Country of ref document: JP

Ref document number: PA/a/2004/000494

Country of ref document: MX

Ref document number: 1020047000696

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002764696

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 530043

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002764696

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097020632

Country of ref document: KR